GSK/GSK
$44.98
0.22%-
1D1W1MYTD1YMAX
About GSK
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
Ticker
GSK
Sector
Healthcare
Trading on
NYSE
Industry
Biotechnology & Drugs
CEO
Emma Walmsley
Employees
70,212
Headquarters
Brentford, United Kingdom
Website
www.gsk.com
GSK Metrics
BasicAdvanced
$93B
Market cap
16.22
P/E ratio
$2.77
EPS
0.67
Beta
-
Dividend rate
3.29%
Dividend yield
Price and volume
Market cap
$93B
Beta
0.67465
52-week high
$45.93
52-week low
$33.33
Average daily volume
3.2M
Financial strength
Current ratio
0.867
Quick ratio
0.58
Long term debt to equity
109.509
Total debt to equity
128.41
Dividend payout ratio (TTM)
53.46%
Enterprise value to free cash flow
37.213
Interest coverage (TTM)
11.37%
Management effectiveness
Return on assets (TTM)
8.13%
Return on equity (TTM)
34.95%
Return on investment (TTM)
12.25%
Valuation
Price to earnings (TTM)
16.222
Price to revenue (TTM)
2.387
Price to book
5.304
Price to free cash flow (TTM)
24.178
Forward dividend yield
3.29%
Growth
Revenue change (TTM)
5.69%
Earnings per share change (TTM)
-0.96%
3-year revenue growth
7.59%
3-year earnings per share growth
2.67%
What the Analysts think about GSK
Analyst Ratings
Majority rating from 7 analysts.
Price Targets
Average projection from 5 analysts.
High $52.50
Low $43.11
$44.98
Current price
$46.39
Average price target
GSK Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
£7.4B
-8.56%
Net income
£1B
198.86%
Profit margin
14.2%
227.19%
GSK Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.97
$1.28
$0.72
$1.09
-
Expected
$0.87
$1.14
$0.76
$0.91
$0.96
Surprise
11.72%
11.93%
-5.66%
20.11%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Upcoming events
FAQs
What’s the current market cap for GSK stock?
GSK (GSK) has a market cap of $93B as of May 20, 2024.
What is the P/E ratio for GSK stock?
The price to earnings (P/E) ratio for GSK (GSK) stock is 16.22 as of May 20, 2024.
Does GSK stock pay dividends?
No, GSK (GSK) stock does not pay dividends to its shareholders as of May 20, 2024.
When is the next GSK dividend payment date?
GSK (GSK) stock does not pay dividends to its shareholders.
What is the beta indicator for GSK?
GSK (GSK) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the GSK stock price target?
The target price for GSK (GSK) stock is $46.39, which is 3.13% above the current price of $44.98. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell GSK stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.